google ads

Transitional Cell Carcinoma: Differential Diagnosis

Large TCC’s may look similar to
  • Infiltrating renal cell carcinoma
  • Lymphoma
  • Metastases
  • Xanthogranulomatous pyelonephritis

 

TCC Kidney

TCC Kidney

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

TCC Left Kidney

TCC Left Kidney

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

TCC of the Kidney and Beyond

  • Ureter
  • Bladder
  • Contralateral kidney

 

“The most common imaging manifestation of transitional cell carcinoma in the ureters is urothelial thickening, particularly focal thickening or a short-segment ureteral stricture. Similar to other sites in the urinary tract, diffuse or bilateral urothelial thickening in the ureters is unlikely to represent malignancy, and is much more likely to represent an ascending urinary tract infection (particularly when associated with diffuse bladder wall thickening secondary to cystitis).”
Upper and Lower Tract Urothelial Imaging Using Computed Tomography Urography
Siva P. Raman, MD*, Elliot K. Fishman
Urol Clin N Am 45 (2018) 389–405

 

“As with other portions of the urinary tract, transitional cell carcinomas in the ureter are often hypovascular, making it critical that the field of view includes the entirety of the ureters during the arterial phase acquisition. Any focal or irregular urothelial hyperenhancement should raise concern for malignancy, and, in some instances, there may be associated tumor neovascularity.”
Upper and Lower Tract Urothelial Imaging Using Computed Tomography Urography
Siva P. Raman, MD*, Elliot K. Fishman
Urol Clin N Am 45 (2018) 389–405

 

“ The hallmark of TCC is multiplicity and recurrence. Nearly 2-4% of patients with bladder cancer develop upper tract TCC, but 40% of patients with upper tract TCC develop bladder cancer.”
Imaging and Staging of Transitional Cell Carcinoma: Part 2, Upper Urinary Tract
Vikram R et al
AJR 2009;192:1488-1493

 

Ureteral TCC

  • 2,290 patients and 700 deaths in 2008
  • Can occur anywhere in the ureter
    • Distal ureter lesions account for ¾ of cases
    • Unfortunately, distal ureter is the most difficult to consistently distend and visualize well.
  • Ureter rarely involved by lymphoma and metastatic disease (breast, GI, prostate, cervix, and RCC)

 

Ureteral TCC: Imaging Findings

  • Urothelial thickening
  • Abnormal urothelial enhancement
    • Particularly when asymmetric, focal, and in conjunction with thickening
  • Ureteral calcification
  • Periureteral fat stranding
  • Discrete filling defect or mass
  • Look for site of transition and proximal hydronephrosis & hydroureter

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Periureteral fat stranding
Extramural spread of tumor
Transitional Cell Carcinoma of the Kidneys

 

Neovascularity secondary to malignancy
Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transition points in the urinary tract secondary to malignancy
Transitional Cell Carcinoma of the Kidneys

 

TCC Left Distal Ureter

TCC Left Distal Ureter

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

TCC Left Ureter

TCC Left Ureter

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

Transitional Cell Carcinoma of the Kidneys

 

 
 

Privacy Policy

Copyright © 2024 The Johns Hopkins University, The Johns Hopkins Hospital, and The Johns Hopkins Health System Corporation. All rights reserved.